Filings/VVOS/10-Q

Source document

EDGAR
Loading document…
KPIsSections17
Headline metrics
Revenue — GREEN$10.3M+50.6% YoY
Gross margin — GREEN58.4%
Net income — GREEN-$13.2M-48.3% YoY
Net margin — GREEN-127.9%
Operating margin — RED-111.1%
Red flags4 red1 orange
Liquidity5
RED
Negative operating cash flowoperating_cf_burn
The company is burning cash from operations — sustainability depends on financing.
RED
Net margin -127.9%net_margin_sharply_negative
Net income margin below -5% — profitability materially negative vs revenue.
RED
Cash conversion (CFO/Rev) -89.0%cash_conversion_weak
CFO/Revenue below 0 — operating model not generating cash despite revenue.
ORANGE
Current ratio 0.21current_ratio_low
Current assets are below current liabilities — short-term liquidity pressure.
RED
Cash runway ~0.2 yearscash_runway_low
At current burn rate, cash covers less than 2 years — may require near-term financing.
Income Statement
Income Statement
MetricValueFlag
Revenue$10.3MGREEN
Revenue (quarter)$5.2MGREEN
Gross Margin58.4%GREEN
Operating Margin-111.1%RED
Net Margin-127.9%GREEN
Net Income-$13.2MGREEN
EPS (diluted)$-0.81GREEN
Balance Sheet
Balance Sheet
MetricValueFlag
Cash$1.8MGREEN
Broad Liquidity$1.8MGREEN
Current Ratio0.21GREEN
Total Assets$24.1MGREEN
Total Equity-$3.8MGREEN
Debt/Equity-0.10GREEN
Cash Flow
Cash Flow
MetricValueFlag
Operating CF-$9.2MGREEN
Cash Conversion (CFO/Rev)-0.89GREEN
SBC % Revenue2.0%GREEN
Free Cash Flow-$9.6MGREEN

Sections in this filing

Financial Statements (unaudited)

Item 1. Financial Statements. VIVOS THERAPEUTICS INC. Unaudited Condensed Consolidated Balance Sheets (In Thousands, Except Per Share Amounts) June 30, 2026 December 31, 2025 Current assets Cash and cash equivalents $ 1,774 $ 2,029 Accounts receivable, net of allowance of $ 1,179 and $ 882 , respectively 1,438 1,581 Prepaid expenses and other current assets 1,001 774 Total current assets 4,213 4,384 Long-term assets Goodwill 8,572 8,572 Property and equipment, net 3,640 3,757 Operating lease right-of-use asset 3,809 4,166 Intangible assets, net 3,638 4,045 Deposits and other 272 228 Total assets $ 24,144 $ 25,152 LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) Current liabilities Accounts payable $ 2,946 $ 1,679 Accrued expenses 7,042 5,988 Contract liabilities 583 479 Current portion of operating lease liability 790 672 Current portion of financing lease liability 56 55 Current portion of debt 7,772 8,353 Other current liabilities 1,200 850 Total current liabilities 20,389 18,076 Long-term liabilities Employee retention credit liability 2,904 2,904 Operating lease liability, net of current portion 3,438 3,840 Financing lease liability, net of current portion 83 113 Debt, net of current portion 366 469 Other liabilities 950 1,300 Total liabilities 28,130 26,702 Commitments and contingencies (Note 12) - - Stockholders’ equity/(deficit) Preferred Stock, $ 0.0001 par value per share. Authorized 50,000,000 shares; 3,608,495 shares issued and outstanding $ - $ - Preferred Stock – additional paid in capital 1,105 - Common Stock, $ 0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 14,531,617 shares as of June 30, 2026 and 9,286,609 shares as December 31, 2025 1 1 Additional paid-in capital 133,599 123,866 Accumulated deficit ( 138,520 ) ( 125,357 ) Total stockholders’ equity/(deficit) ( 3,815 ) ( 1,490 ) Non-controlling interest ( 171 ) ( 60 ) Total equity/(deficit) ( 3,986 ) ( 1,550 ) Total liabilities and equity/(deficit) $ 24,144 $ 25,152 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Field: Page; Sequence: 5; Options: NewSection; Value: 1 Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence Field: /Page VIVOS THERAPEUTICS INC. Unaudited Condensed Consolidated Statements of Operations (In Thousands, Except Per Share Amounts) 2026 2025 2026 2025 Three Months Ende